The status of sciaenid fishery in Orissa coast during i984-'95 with special reference to trawl catch

The croakers form an important demersal fishery resource of India. The sciaenid fishery in India during the decade 1984-'95 which had been yielding 1,22,464 tonnes annually formed 6.16% of the average marine fish production of the country. The state-wise analysis during the period showed that 12.28% of the country's sciaenid catch came from Orissa, where its annual average was 14,680 tonnes forming 29.21% of the total fish production

Marine fish landings at Veraval

Veraval is the most important fish landing centre of Gujarat. The average annual contribution of Veraval to the landing of Gujarat is about 32%.The commercially important resources landed at Veraval were sharks, cat fishes, croakers, ribbonfishes, penaeid prawns, non- penaid prawns, crabs and cephalopods

Marine fisheries in Gujarat

A brief account of marine fish landings in Gujarat during 1985- 95 is given in this paper. Contribution of different gears along with the CPUE and the regionwise as well as groupwise details are also presented. The status and prospect of marine fisheries ofihe state is discussed with the aid of last 5 decades landing data

Marine fisheries of Orissa

A brief account of marine fish landings in Orissa during 1985 to 1995 is given in this paper. Gearwise, groupwise and districtwise marine fish landings in this state was also discussed together with a critical analysis of marine fishery of the state during the last five decade

Trends in the catch of silverbellies by mechanised boats In Tamil Nadu during 1971-75

Silverbellies form an important demersal fishery of India particularly on the coasts of southern maritime states, the annual average catch amounting to about 3% of the total marine fish CEtoh ia India. In Tamil Nadai, mechanised boats predominantly operate at iRoyapuram (Kasimedai), Cuddflore, Portonovo, Adirampatnarri, Mandapam, Rameswaram and land considerable quantities of silverbellies. The catch trends of silverbellies landed by the mechanised boats in Tamil Nadu during the period 1971 to 1975 and the relation between the index of abundance and the toU'l fishing effort both in respect of total landings and landings of silverbellies are dealt with in the present paper.

An Appraisal of the Marine Fisheries of Karnataka and Goa

Karnataka, on the West coast, plays an important role in the fisheries development of India and has a prominent place in the country's fisheries map, It has a shelf area of 25000 Sq. Km. and a coastline of 270 Km, about 1/22 of the country's coastline. The State's contribution to the total marine fish production in the country is of the order of ^.0%. The State has two coastal districts, namely Dakshin Kannada and Uttar Kannada. The lengths of coastline of both the districts are almost the same. Many rivers such as the Nethravathi, the Saravathi and the Kali flow into the Arabian sea and render the inshore area rich in nutrients

Estimated marine fish landings (in tonnes)in India during 2002 and 2003

Estimated marine fishing landing in India during 2002 and 2003 is 2.59 and 2.58 millon tonnes respectively. Gear wise landing were also estimated during this period

Quadrupolar interactions in Pr compounds: PrFe4P12 and PrBa2Cu3O6

We examine trivalent Pr crystal field models with near-degeneracy of the two lowest crystal field levels, where interaction-induced quadrupolar and dipolar moments are as important as the permanent moments of the crystal field ground state. We find that the Gamma1-Gamma4 level scheme yields a successful description of the antiferroquadrupolar ordering of PrFe4P12. For PrBa2Cu3O6, we argue that quadrupolar interaction is important for understanding the Pr ordering transition at 11K.Comment: One of the figures, and a few sentences replaced. 8 pages, 5 figures, iopart submitted to the Proceedings of the conference on "Advances in the Physics of f-electron Systems (JAERI Tokai, Japan), accepted for publication in J. Phys.: Condensed Matte

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

Aims  The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin–kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (≥1.8 mmol/L) despite intensive statin therapy. In a pre-specified analysis, we assessed the effects of alirocumab on types of MI. Methods and results  Median follow-up was 2.8 years. Myocardial infarction types were prospectively adjudicated and classified. Of 1860 total MIs, 1223 (65.8%) were adjudicated as Type 1, 386 (20.8%) as Type 2, and 244 (13.1%) as Type 4. Few events were Type 3 (n = 2) or Type 5 (n = 5). Alirocumab reduced first MIs [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.77–0.95; P = 0.003], with reductions in both Type 1 (HR 0.87, 95% CI 0.77–0.99; P = 0.032) and Type 2 (0.77, 0.61–0.97; P = 0.025), but not Type 4 MI. Conclusion  After ACS, alirocumab added to intensive statin therapy favourably impacted on Type 1 and 2 MIs. The data indicate for the first time that a lipid-lowering therapy can attenuate the risk of Type 2 MI. Low-density lipoprotein cholesterol reduction below levels achievable with statins is an effective preventive strategy for both MI types.For complete list of authors see http://dx.doi.org/10.1093/eurheartj/ehz299</p

Effect of alirocumab on mortality after acute coronary syndromes. An analysis of the ODYSSEY OUTCOMES randomized clinical trial

Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome. Methods: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy. Alirocumab dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL. We examined the effects of treatment on all-cause death and its components, cardiovascular and noncardiovascular death, with log-rank testing. Joint semiparametric models tested associations between nonfatal cardiovascular events and cardiovascular or noncardiovascular death. Results: Median follow-up was 2.8 years. Death occurred in 334 (3.5%) and 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85; 95% CI, 0.73 to 0.98; P=0.03, nominal P value). This resulted from nonsignificantly fewer cardiovascular (240 [2.5%] vs 271 [2.9%]; HR, 0.88; 95% CI, 0.74 to 1.05; P=0.15) and noncardiovascular (94 [1.0%] vs 121 [1.3%]; HR, 0.77; 95% CI, 0.59 to 1.01; P=0.06) deaths with alirocumab. In a prespecified analysis of 8242 patients eligible for ≥3 years follow-up, alirocumab reduced death (HR, 0.78; 95% CI, 0.65 to 0.94; P=0.01). Patients with nonfatal cardiovascular events were at increased risk for cardiovascular and noncardiovascular deaths (P<0.0001 for the associations). Alirocumab reduced total nonfatal cardiovascular events (P<0.001) and thereby may have attenuated the number of cardiovascular and noncardiovascular deaths. A post hoc analysis found that, compared to patients with lower LDL-C, patients with baseline LDL-C ≥100 mg/dL (2.59 mmol/L) had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71; 95% CI, 0.56 to 0.90; Pinteraction=0.007). In the alirocumab group, all-cause death declined wit h achieved LDL-C at 4 months of treatment, to a level of approximately 30 mg/dL (adjusted P=0.017 for linear trend). Conclusions: Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is maintained for ≥3 years, if baseline LDL-C is ≥100 mg/dL, or if achieved LDL-C is low. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01663402